Breast Cancer

P=N/A, N=50, Recruiting, University of California, Davis

P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026

P2, N=51, Not yet recruiting, Novartis Pharmaceuticals

P=N/A, N=100, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

Carriers with rs17655 minor allele have higher susceptibility to breast cancer for the dominant model. But no significant relationship was observed between rs17655 and breast cancer susceptibility in Caucasian, African, and Asia populations.

Cross-cancer immunotherapy analyses revealed that MTFR1 exhibited improved predictive performance for anti-PD-1 response during the on-treatment phase compared with pretreatment settings. This study elucidates the multidimensional role of MTFR1 as a putative oncogene in BRCA, highlighting it as a promising prognostic biomarker and therapeutic target.

With this technology, we developed trastuzumab deruxtecan, the first DXd-ADC directed toward HER2. Additionally, Dato-DXd showed TROP2-dependent antitumor activity in multiple human cancer cell line-derived and patient-derived xenograft mouse models. Clinically, the global phase III trial targeting hormone receptor-positive, HER2-negative, unresectable or recurrent breast cancer led to its first approval in Japan in December 2024, followed by the approvals in the US and Europe later.

Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.

In contrast, TROP2-directed ADCs demonstrate negligible cardiac signals. Given the elevated fatality rate of serious cardiac events associated with T-DXd observed in real-world data, we propose a risk-stratified cardiac monitoring algorithm incorporating high-sensitivity troponin and global longitudinal strain for patients receiving next-generation ADCs.

Present findings are from a small sample cohort and need further validation from a larger cohort. The online version contains supplementary material available at 10.1007/s13193-025-02427-0.

Eleven cases were positive (7.3%) with weak to intermediate score while all the cases of breast carcinoma (150/150; 100%) expressed TRPS-1 with intermediate to high scores. It was concluded that TRPS1 is 100% sensitive and 92.66% specific for breast carcinoma and can be included in the panel for search of unknown primary at metastatic site.

LARP1 plays a pivotal oncogenic role in BRCA progression by enhancing cell proliferation and immune evasion through mitochondrial regulation and macrophage polarization. These findings highlight LARP1 as a promising a potential therapeutic target, and diagnostic, immunological, prognostic biomarker for BRCA.